6 Leveraged Biotech ETFs

Biotech is one of the most binary corners of the equity market. A single FDA decision, trial readout, or label expansion can swing an individual name double digits in a session. The sector also draws cycle-sensitive capital depending on rates and risk appetite. Mega-caps like Amgen, Gilead, Vertex, and Regeneron anchor the indices, while small and mid-caps drive most of the day-to-day volatility. That setup makes leveraged and inverse biotech ETFs a popular way for traders to express short-term sector views.

The flagship 3x leveraged biotech ETF — the largest and most liquid of the bunch, with weekly options and deep daily volume. LABU tracks 3x the daily performance of the S&P Biotechnology Select Industry Index, an equal-weight basket of US biotech names that mixes small/mid-caps with the larger players. The equal-weight design means single-name blowups (or breakthroughs) hit harder than they would in a cap-weighted fund.

The 2x bullish alternative — BIB targets twice the daily return of the Nasdaq Biotechnology Index (NBI), which leans more heavily on mega-cap biotech names like Amgen, Gilead, Regeneron, and Vertex than LABU's equal-weight S&P benchmark. Launched in 2010, it's one of the older leveraged biotech products on the market and a calmer way to play the bull thesis than the 3x funds.

A more concentrated bullish play — TBXU offers 2x daily upside on the top 5 biotech names equal-weighted, rather than the full sector index. The equal-weight structure means the smallest of the five carries the same load as the largest, which can amplify dispersion around earnings and FDA events. Launched in October 2025, so it's still building liquidity and bid-ask spreads can be wide. Note: there is no inverse counterpart (no TBXD).

Not a typical leveraged ETF — BIOY is an income product that sells put credit spreads against a 3x long biotech ETF to generate weekly distributions. It's not a directional bet on biotech; it's a way to harvest options premium from the volatility around the 3x bull product. Launched in May 2026 and still very young, so the distribution track record is short and liquidity is thin.

The heavyweight inverse bet on the sector — LABD delivers -3x the daily return of the S&P Biotechnology Select Industry Index. Traders use it to hedge or speculate during biotech selloffs (often around binary FDA decisions or risk-off macro moves). Weekly options and reasonable volume, but daily resets cause meaningful decay over longer holding periods — strictly a tactical tool.

The 2x inverse counterpart to BIB — same Nasdaq Biotechnology Index, dialed to -2x daily. Smaller and less liquid than LABD, but the milder leverage and large-cap index tilt mean less day-to-day whippiness. Mostly used by ProShares-loyal traders hedging Nasdaq biotech exposure without committing to the full 3x inverse.